Most people taking drugs like Ozempic and Wegovy have shed significant pounds. But obesity experts say that roughly 20% of ...

StudyFinds' Dr. Faith Coleman explains what happens when patients stop taking popular weight loss medications.

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

The rising popularity of appetite suppressant ‘obesity drugs’ is causing people to eat less when dining out. Is this a threat ...

Biohaven's pipeline includes Troriluzole for SCA, BHV-2100 for migraines, and Taldefgrobep Alfa for SMA. See why BHVN stock ...

North Carolina stopped covering weight loss drugs such as Ozempic for state employees without diabetes. But it extended ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

This summary covers recent developments in the health sector, including studies on thyroid medications and asthma drugs, ...